MCID: URM002
MIFTS: 53

Uremia

Categories: Nephrological diseases

Aliases & Classifications for Uremia

MalaCards integrated aliases for Uremia:

Name: Uremia 12 77 56 45 15 17 74
Uremia of Renal Origin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4676
MeSH 45 D014511
SNOMED-CT 69 44730006
ICD10 34 N19
UMLS 74 C0041948

Summaries for Uremia

MalaCards based summary : Uremia, also known as uremia of renal origin, is related to hyperparathyroidism and hyperphosphatemia. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Ca, cAMP and Lipid Signaling. The drugs Histamine and Fexofenadine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and brain, and related phenotypes are cellular and cardiovascular system

Wikipedia : 77 Uremia is the condition of having high levels of urea in the blood. Urea is one of the primary... more...

Related Diseases for Uremia

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 30.6 CASR EPO PTH TNFRSF11B VDR
2 hyperphosphatemia 30.3 CASR PTH VDR
3 renal osteodystrophy 30.3 CASR PTH TNFRSF11B VDR
4 osteomalacia 30.2 CASR PTH VDR
5 arteriosclerosis 30.1 CRP INS SPP1
6 hypertriglyceridemia, familial 30.0 APOC3 INS LPL
7 sleep apnea 30.0 CRP INS LEP
8 bone disease 30.0 B2M CASR PTH SPP1 TNFRSF11B VDR
9 burns 30.0 ALB INS
10 arteries, anomalies of 29.9 ALB CRP INS LEP VWF
11 pancreatitis 29.9 CASR CRP LPL
12 primary hyperparathyroidism 29.9 ALB CASR PTH VDR
13 pulmonary embolism 29.9 ALB CRP VWF
14 arthropathy 29.9 B2M CRP TNFRSF11B
15 bone resorption disease 29.9 PTH SPP1 TNFRSF11B VDR
16 multiple endocrine neoplasia, type i 29.8 CASR INS PTH
17 insulin-like growth factor i 29.8 GHR INS LEP
18 parathyroid adenoma 29.8 CASR PTH VDR
19 hyperglycemia 29.7 ALB INS LEP
20 end stage renal failure 29.7 ALB CRP EPO LEP PTH
21 myeloma, multiple 29.6 ALB B2M CRP EPO TNFRSF11B
22 glucose intolerance 29.5 CRP INS LEP LPL RETN
23 cerebrovascular disease 29.5 CRP INS VWF
24 heart disease 29.4 ALB APOC3 CRP INS LPL VWF
25 diabetes mellitus 29.2 ALB CRP EPO INS LEP LPL
26 myocardial infarction 28.9 ALB APOC3 CRP INS RETN VWF
27 kidney disease 28.6 ALB APOC3 B2M CASR CRP EPO
28 chronic kidney failure 28.6 ALB B2M CASR CRP EPO INS
29 coronary heart disease 1 28.6 APOC3 CRP INS LPL RETN
30 diabetes mellitus, noninsulin-dependent 28.4 AHSG ALB APOC3 CRP INS LEP
31 vascular disease 28.3 ALB CRP INS LPL NOS2 RETN
32 hypertension, essential 28.3 ALB INS LEP LPL NOS2 RETN
33 lipid metabolism disorder 28.2 APOC3 CRP INS LEP LPL RETN
34 nephronophthisis 1 11.3
35 malignant otitis externa 10.5 CRP INS
36 severe nonproliferative diabetic retinopathy 10.4 ALB INS
37 gastrointestinal tuberculosis 10.4 ALB CRP
38 abdominal tuberculosis 10.4 ALB CRP
39 immunodeficiency 43 10.4 ALB B2M
40 scleredema adultorum 10.4 INS PTH
41 pyuria 10.4 ALB CRP
42 fibrogenesis imperfecta ossium 10.4 PTH TNFRSF11B
43 folic acid deficiency anemia 10.4 CRP EPO
44 fetal erythroblastosis 10.4 ALB EPO INS
45 analbuminemia 10.4 ALB CRP EPO
46 hypocalciuric hypercalcemia, familial, type i 10.4 CASR PTH
47 pleural disease 10.3 ALB CRP SPP1
48 hypocalciuric hypercalcemia, familial, type iii 10.3 CASR PTH
49 secondary hyperparathyroidism 10.3
50 orthostatic proteinuria 10.3 ALB B2M

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia

Symptoms & Phenotypes for Uremia

MGI Mouse Phenotypes related to Uremia:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ALB B2M CASR EPO GHR INS
2 cardiovascular system MP:0005385 10.36 B2M CRP EPO GHR INS LEP
3 homeostasis/metabolism MP:0005376 10.36 AHSG ALB B2M CASR CRP EPO
4 immune system MP:0005387 10.28 B2M CASR CRP EPO GHR INS
5 growth/size/body region MP:0005378 10.27 AHSG B2M CASR GHR INS LEP
6 hematopoietic system MP:0005397 10.26 B2M CASR EPO GHR INS LEP
7 endocrine/exocrine gland MP:0005379 10.16 ALB B2M CASR GHR INS LEP
8 digestive/alimentary MP:0005381 10.13 ALB B2M CASR INS LEP NOS2
9 integument MP:0010771 10.1 B2M CASR EPO GHR INS LEP
10 mortality/aging MP:0010768 10.1 ALB B2M CASR EPO GHR INS
11 adipose tissue MP:0005375 10.03 GHR INS LEP LPL NOS2 RETN
12 liver/biliary system MP:0005370 10.02 ALB B2M EPO GHR INS LEP
13 limbs/digits/tail MP:0005371 9.91 AHSG EPO GHR LEP PTH TNFRSF11B
14 muscle MP:0005369 9.9 AHSG ALB CASR EPO GHR INS
15 renal/urinary system MP:0005367 9.56 ALB CASR GHR INS LEP NOS2
16 skeleton MP:0005390 9.36 AHSG CASR EPO GHR INS LEP

Drugs & Therapeutics for Uremia

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
3
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
leucovorin Approved Phase 4 58-05-9 143 6006
6
Metformin Approved Phase 4 657-24-9 14219 4091
7
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
8
tannic acid Approved Phase 4 1401-55-4
9
carbamide peroxide Approved Phase 4 124-43-6
10
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Pamidronate Approved Phase 4 40391-99-9 4674
13
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
16 Central Nervous System Depressants Phase 4,Not Applicable
17 Histamine H1 Antagonists Phase 4
18 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
19 Calcium, Dietary Phase 4,Phase 2
20
Histamine Phosphate Phase 4 51-74-1 65513
21 Histamine Antagonists Phase 4
22 Histamine H1 Antagonists, Non-Sedating Phase 4
23 Anti-Anxiety Agents Phase 4,Not Applicable
24 Anti-Allergic Agents Phase 4
25 Hormones Phase 4,Phase 2,Not Applicable
26 Psychotropic Drugs Phase 4,Not Applicable
27 Analgesics Phase 4,Phase 3,Not Applicable
28 Tranquilizing Agents Phase 4,Not Applicable
29 Neurotransmitter Agents Phase 4,Not Applicable
30 calcium channel blockers Phase 4
31 Anticonvulsants Phase 4,Not Applicable
32 Hormone Antagonists Phase 4,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Micronutrients Phase 4,Phase 2
36 Vitamin B Complex Phase 4
37 Vitamins Phase 4,Phase 2
38 Folate Phase 4
39 Nutrients Phase 4,Phase 2
40 Trace Elements Phase 4,Phase 2
41 Hematinics Phase 4
42 Vitamin B9 Phase 4
43 Protective Agents Phase 4,Phase 1,Phase 2
44 Antioxidants Phase 4,Phase 1,Phase 2
45 Polymethyl Methacrylate Phase 4
46 Vasodilator Agents Phase 4
47 Hypoglycemic Agents Phase 4,Phase 2
48 Incretins Phase 4
49 Dialysis Solutions Phase 4,Phase 3,Phase 2
50 Epoetin alfa Phase 4 113427-24-0

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Probiotics Use in the Chronic Peritoneal Dialysis Patients Unknown status NCT01076426 Phase 4 Pro-biotics
2 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
3 Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events Completed NCT00317005 Phase 4 folate treatment
4 Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients Completed NCT01356433 Phase 4 oral vitamin C;oral vitamin C
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed NCT00513630 Phase 4 Glipizide;Metformin
7 Heat Disinfection of HD Water Treatment System in Hemodialysis Patients Completed NCT01138280 Phase 4
8 Hannover Dialysis Outcome Study Completed NCT00529139 Phase 4
9 Very Low Protein Diet or Dialysis in Uremic Elderly? Completed NCT00388648 Phase 4 mixture of amino and keto acids
10 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
11 Liraglutide Treatment to Patients With Severe Renal Insufficiency Completed NCT01394341 Phase 4 Liraglutide
12 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
13 STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE Completed NCT00278057 Phase 4 dialysisis with and without glucose in the dialysis
14 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
15 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
16 Erythropoietin in Hemolytic Uremic Syndrome Not yet recruiting NCT03776851 Phase 4 erythropoietin
17 Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Unknown status NCT02976688 Phase 2, Phase 3
18 Nafamostat Efficacy and Safety in Critically Ill Patients(NICE) Unknown status NCT01486485 Phase 3 heparinized saline priming group;nafamostat infusion after heparinized saline priming
19 The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
20 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
21 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
22 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
23 Micro-elimination of Hepatitis C Virus Infection in Uremics Recruiting NCT03891550 Phase 3 Epclusa
24 Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Recruiting NCT03205995 Phase 3
25 Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting NCT03131219 Phase 3
26 rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study Recruiting NCT03829449 Phase 3 rVA576 (Coversin)
27 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Active, not recruiting NCT02949128 Phase 3
28 Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome Terminated NCT00004465 Phase 3 SYNSORB Pk;Placebo
29 The Plasma Large-Volume Exchange RCT Withdrawn NCT01433003 Phase 3
30 Effect of SVF Derived MSC in DCD Renal Transplantation Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
31 Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
32 Effect of BM-MSCs in DCD Kidney Transplantation Unknown status NCT02561767 Phase 1, Phase 2 Induction therapy (ATG or Basiliximab);Maintenance therapy (Low-dose CNI + MPA + steroids)
33 Treatment of Uremic Pruritus by Olive-omega 3 Ointment Unknown status NCT01447693 Phase 1, Phase 2
34 Induction With SVF Derived MSC in Living-related Kidney Transplantation Unknown status NCT02492308 Phase 1, Phase 2 Basiliximab induction
35 Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Unknown status NCT01876017 Phase 1, Phase 2
36 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
37 L-Cysteine in Peritoneal Dialysis Completed NCT02050139 Phase 2
38 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
39 Omega-3 Fatty Acid Administration in Dialysis Patients Completed NCT00655525 Phase 2
40 Vitamin D, Insulin Resistance and Inflammation in ESRD Completed NCT00656032 Phase 2
41 Role of Turmeric on Oxidative Modulation in ESRD Patients Completed NCT01906840 Phase 1, Phase 2 Turmeric;placebo
42 Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Completed NCT00309257 Phase 2 ACE I, ATA II and Statins;Benazepril, Valsartan and Fluvastatin
43 Sevelamer in Proteinuric CKD Completed NCT01968759 Phase 2 Sevelamer;Ramipril and Irbesartan
44 A Study in Participants With End-Stage Renal Disease Completed NCT01200290 Phase 2 LY2127399
45 The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) Completed NCT01757431 Phase 2 Eculizumab
46 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed NCT01194973 Phase 2 Eculizumab
47 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed NCT01193348 Phase 2 Eculizumab
48 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed NCT00844844 Phase 2 Eculizumab
49 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed NCT00844545 Phase 2 Eculizumab
50 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed NCT00844428 Phase 2 eculizumab

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: uremia

Genetic Tests for Uremia

Anatomical Context for Uremia

MalaCards organs/tissues related to Uremia:

42
Kidney, Testes, Brain, Endothelial, Monocytes, Pancreas, Skeletal Muscle

Publications for Uremia

Articles related to Uremia:

(show top 50) (show all 2492)
# Title Authors Year
1
Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. ( 30145224 )
2019
2
Uremia presented as acute cranial neuropathy. ( 30707316 )
2019
3
Two-dimensional speckle tracking to image ventricular-arterial coupling in uremia. ( 30411403 )
2019
4
Influence of colonic dialysis using Gubenxiezhuo on the distribution of gut microflora in uremia rats. ( 30536550 )
2019
5
Unstable blood sugar levels as triggers for the syndrome of acute bilateral basal ganglia lesions in diabetic uremia: Two Taiwanese patients with unusual neuroimaging findings. ( 30723812 )
2019
6
Assessment of the left ventricular function in patients with uremia using layer-specific 2-dimensional speckle tracking echocardiography. ( 30817588 )
2019
7
Therapeutic Prospective of a Spore-Forming Probiotic-Bacillus clausii UBBC07 Against Acetaminophen-Induced Uremia in Rats. ( 30879230 )
2019
8
A biophysical insight into structural and functional state of human serum albumin in uremia mimic milieu. ( 30904532 )
2019
9
PON-1 carbamylation is enhanced in HDL of uremia patients. ( 30987726 )
2019
10
Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets. ( 31086003 )
2019
11
Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review. ( 30407278 )
2018
12
Evaluation of the different surgical parathyroidectomies on secondary hyperparathyroidism in uremia patients. ( 29205012 )
2018
13
CRP, IL‑2 and TNF‑α level in patients with uremia receiving hemodialysis. ( 29257244 )
2018
14
Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. ( 29304096 )
2018
15
Uremia: A historical reappraisal of what happened
. ( 29451473 )
2018
16
Evaluation of carotid artery elasticity in patients with uremia by echo tracking. ( 29453675 )
2018
17
Carmelo Giordano (1930-2016): uremia therapy by low protein alimentation and sorbents. ( 29482271 )
2018
18
RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. ( 29529595 )
2018
19
Risk factors of the peptic ulcer bleeding in aging uremia patients under regular hemodialysis. ( 29778548 )
2018
20
Uremia increases QRS duration after β-adrenergic stimulation in mice. ( 29984555 )
2018
21
Depressive Symptoms in Dialysis: Prevalence and Relationship with Uremia-Related Biochemical Parameters. ( 30048984 )
2018
22
Preliminary study of Bim on the early diagnosis and prognosis of the elderly uremia with gastrointestinal nutrition combined with dialysis. ( 30058698 )
2018
23
Uremia induces upregulation of cerebral tissue oxidative/inflammatory cascade, down-regulation of Nrf2 pathway and disruption of blood brain barrier. ( 30093950 )
2018
24
Cannabinoid Hyperemesis Syndrome Masquerading as Uremia: An Educational Case Report. ( 30159161 )
2018
25
Increased electronegativity of high-density lipoprotein in uremia patients impairs its functional properties and is associated with the risk of coronary artery disease. ( 30278357 )
2018
26
Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. ( 30301260 )
2018
27
Homocysteine Aggravates Intestinal Epithelial Barrier Dysfunction in Rats with Experimental Uremia. ( 30336454 )
2018
28
Serum and Lipoprotein Particle miRNA Profile in Uremia Patients. ( 30400676 )
2018
29
MicroRNA-142-3p improves vascular relaxation in uremia. ( 30453118 )
2018
30
Efficacy of linalool to ameliorate uremia induced vascular calcification in wistar rats. ( 30466616 )
2018
31
WISP1 silencing confers protection against epithelial-mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/β-catenin signaling pathway in uremia. ( 30556898 )
2018
32
Severe Acute Kidney Injury With Significant Uremia in an Infant Found to Have Inferior Vena Cava, Bilateral Renal Vein, and Bilateral Renal Artery Thromboses. ( 30559631 )
2018
33
Asymptomatic Brain Edema after Hemodialysis Initiation in a Patient with Severe Uremia. ( 28553356 )
2017
34
Sudden bilateral vision loss as the sole manifestation of posterior reversible encephalopathy syndrome from acute uremia: Clinical case report. ( 28682904 )
2017
35
Simultaneous liver, pancreas-duodenum and kidney transplantation in a patient with hepatitis B cirrhosis, uremia and insulin dependent diabetes mellitus. ( 29259387 )
2017
36
Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. ( 28680087 )
2017
37
Aphasic Status Epilepticus Associated with Uremia. ( 29344470 )
2017
38
Persistence of Vascular Calcification after Reversal of Uremia. ( 27939134 )
2017
39
Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. ( 27992874 )
2017
40
Lion face in a uremia patient. ( 28011855 )
2017
41
Co-Expression Analysis of Blood Cell Genome Expression to Preliminary Investigation of Regulatory Mechanisms in Uremia. ( 28050009 )
2017
42
Uremia modulates the phenotype of aortic smooth muscle cells. ( 28107707 )
2017
43
Bilateral rectal sheath hematomas after low-molecular weight heparin treatment in uremia. ( 28330422 )
2017
44
Research progress about effects of myocardial enzyme and troponin on uremia with acute left ventricular failure. ( 28338189 )
2017
45
Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. ( 28341272 )
2017
46
ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. ( 28351665 )
2017
47
Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. ( 28376076 )
2017
48
Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. ( 28523279 )
2017
49
"Uremic Toxin" Section in the Journal Toxins: A Powerful Tool to Bundle and Advance Knowledge on Uremia. ( 28524108 )
2017
50
Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction. ( 28605780 )
2017

Variations for Uremia

Expression for Uremia

Search GEO for disease gene expression data for Uremia.

Pathways for Uremia

GO Terms for Uremia

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 AHSG ALB APOC3 B2M CRP EPO
2 cell surface GO:0009986 9.77 B2M CASR EPO GHR LPL
3 endoplasmic reticulum lumen GO:0005788 9.55 AHSG ALB B2M INS SPP1
4 extracellular space GO:0005615 9.47 AHSG ALB APOC3 B2M CRP EPO
5 platelet alpha granule lumen GO:0031093 9.43 AHSG ALB VWF
6 chylomicron GO:0042627 9.32 APOC3 LPL

Biological processes related to Uremia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 B2M LPL PTH TNFRSF11B
2 platelet degranulation GO:0002576 9.79 AHSG ALB VWF
3 cellular calcium ion homeostasis GO:0006874 9.74 CASR PTH VDR
4 response to nutrient GO:0007584 9.72 EPO LEP TNFRSF11B
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 EPO GHR LEP
6 skeletal system development GO:0001501 9.67 AHSG PTH TNFRSF11B VDR
7 high-density lipoprotein particle remodeling GO:0034375 9.61 ALB APOC3
8 negative regulation of lipid catabolic process GO:0050995 9.61 APOC3 INS
9 positive regulation of glycogen biosynthetic process GO:0045725 9.6 INS PTH
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.59 INS LEP
11 hormone metabolic process GO:0042445 9.58 GHR LEP
12 intestinal absorption GO:0050892 9.56 LEP VDR
13 cellular protein metabolic process GO:0044267 9.55 AHSG ALB B2M INS SPP1
14 negative regulation of blood vessel diameter GO:0097756 9.54 CRP INS
15 negative regulation of lipid storage GO:0010888 9.52 CRP LEP
16 regulation of signaling receptor activity GO:0010469 9.5 EPO INS LEP PTH RETN SPP1
17 chylomicron remodeling GO:0034371 9.49 APOC3 LPL
18 negative regulation of feeding behavior GO:2000252 9.48 INS RETN
19 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
20 regulation of cytokine production involved in inflammatory response GO:1900015 9.43 LEP NOS2
21 interleukin-8 secretion GO:0072606 9.4 LEP NOS2
22 prostaglandin secretion GO:0032310 9.32 LEP NOS2
23 interleukin-6 secretion GO:0072604 9.26 LEP NOS2
24 acute-phase response GO:0006953 8.92 AHSG CRP EPO INS

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB B2M CRP GHR INS VWF
2 hormone activity GO:0005179 9.02 EPO INS LEP PTH RETN
3 peptide hormone receptor binding GO:0051428 8.96 LEP PTH

Sources for Uremia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....